醫療用嗎啡的全球市場的預測(～2030年)

在預測期內，全球醫用嗎啡市場規模預計將以 7.20% 的健康復合年增長率增長。心血管疾病、關節炎和惡性腫瘤等各種疾病的止痛藥治療不斷增加是市場發展的主要貢獻者。不斷增長的老齡化人口也推動了患者人數的增加和市場准入的增加。

本報告提供全球醫療用嗎啡市場相關調查分析，提供市場動態，地區和市場區隔的分析，企業簡介等資訊。

目錄

第1章 報告開端

第2章 市場簡介

第3章 調查手法

第4章 市場動態

• 促進因素
• 阻礙因素
• 機會
• 課題
• 宏觀經濟指標
• 技術趨勢與評估

第5章 市場要素的分析

• 波特的五力分析
• 價值鏈分析
• 投資可行性分析
• 價格分析

第6章 全球醫療用嗎啡市場:各給藥途徑

• 簡介
• 口服
• 注射
• 其他

第7章 全球醫療用嗎啡市場:各用途

• 簡介
• 關節炎
• 癌症
• 心肌梗塞
• 腎臟結石
• 腹瀉
• 其他

第8章 全球醫療用嗎啡市場:各流通管道

• 簡介
• 醫院藥局
• 零售藥局
• 線上藥局
• 其他

第9章 全球醫療用嗎啡市場:各終端用戶

• 簡介
• 醫院·診療所
• 門診病人手術中心
• 居家照護
• 其他

第10章 全球醫療用嗎啡市場:各地區

• 簡介
• 美國
  • 北美
  • 南美
• 歐洲
  • 西歐
  • 東歐
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 大韓民國
  • 其他的亞太地區
• 中東·非洲
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 阿曼
  • 科威特
  • 卡達
  • 中東·非洲

第11章 企業形勢

• 簡介
• 市場佔有率分析
• 主要的發展·策略

第12章 企業簡介

• MALLINCKRODT PHARMACEUTICALS
• ALCALIBER S.A.
• PURDUE PHARMA L.P.
• PFIZER INC.
• JOHNSON MATTHEY FINE CHEMICALS
• SUN PHARMACEUTICAL INDUSTRIES LTD.
• VERVE HEALTH CARE LTD.
• TAJ PHARMACEUTICALS LIMITED
• NORTHEAST PHARM
• MANUS AKTTEVA BIOPHARMA LLP

第13章 附錄

Medical Morphine Market Forecast till 2030

Market Overview

The Medical Morphine Market is supposed to register a healthy CAGR of 7.20% during the forecast time frame. The market development is fundamentally credited to the rising remedy of pain relievers for different diseases like cardiovascular problems, joint inflammation, or malignant growth. The developing geriatric populace additionally prompts an expansion in the patient populace and expanded market entrance by the market players.

Morphine is much of the time viewed as one of the most proficient painkillers. Likewise, its utilization in the therapy of extreme or constant torment related to cutting-edge medical circumstances is generally acknowledged in many nations of the world. Moreover, cardiovascular sicknesses guaranteed north of 801,000 lives in the US in the year 2014. Likewise, the rising use of pain relievers to ease torment in medical procedures is supposed to fuel the worldwide medical morphine market development. The ascent in the utilization of morphine for torment treatment is a key element adding to the market's development. Additionally, its utilization in the treatment of extreme and persistent agony related to a high-level medical condition is generally acknowledged in many regions across the globe. In addition, the expanded predominance of muscular diseases like elbow torment, joint pain, fibromyalgia, and osteoporosis is the key explanation driving the medical morphine market esteem extension.

Market Segmentation

The global medical morphine market is segmented into the distribution channel, application, route of administration, and end-user.

The route of administration segment is further bifurcated into Oral and Injectables types. The distribution channel segment is classified into Online pharmacy, Hospital pharmacy, Retail pharmacy, and Others.

The application segment is further classified into Myocardial infarction, Diarrhea, Arthritis, Kidney stones, Cancer, and Others. By end-user, the market is categorized into Ambulatory surgical centers, Hospitals and clinics, and home care.

Regional Analysis

The Americas is likely to lead the market. The expanded recurrence of joint pain or other fiery circumstances, and a rising geriatric populace, are supposed to support the market development in the American region. Also, factors like expanded endeavors by the public authority and ventures for innovative work in creative medical therapy options are supposed to help the development of the medical morphine market in the region.

The expansion in cardiovascular issues and joint inflammation is projected to straightforwardly affect restorative morphine interest, which is utilized to decrease joint agony and post-careful distress. Europe is supposed to be the second-biggest medical morphine market and may possess a sizable extent of the worldwide market over the forecast years. The European market is probably going to grow at a consistent speed through the forecast years, considering the productive extension of the medical care industry and the rising rates of joint pain. Besides, the rising provocative sicknesses, and a geriatric populace that prompts an expansion in the understanding pool, are powering market extension.

Over the forecast years, the Asia Pacific region is anticipated to be the fastest-developing morphine market. The rising rate of constant diseases like cardiovascular issues is one of the essential variables of market development. China is anticipated to be the quickest developing country, due to a growing populace, eventually rising patient pool, and the availability of inventive treatment choices. Likewise, expanded well-being consumption in the space is supporting the development of the Asia Pacific medical morphine market.

Key Players

The key companies that offer medical morphine in the global market include Taj Pharmaceuticals Limited, Johnson Matthey Fine Chemicals, Alcaliber S.A, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Mallinckrodt Pharmaceuticals, Purdue Pharma L.P., MANUS AKTTEVA BIOPHARMA LLP, Verve Health Care Ltd., and NORTHEAST PHARM

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
  • 2.2.1 RESEARCH OBJECTIVE
  • 2.2.2 ASSUMPTIONS
  • 2.2.3 LIMITATIONS

3. RESEARCH METHODOLOGY

• 3.1 INTRODUCTION
• 3.2 PRIMARY RESEARCH
• 3.3 SECONDARY RESEARCH
• 3.4 MARKET SIZE ESTIMATION

4. MARKET DYNAMICS

• 4.1 DRIVERS
• 4.2 RESTRAINTS
• 4.3 OPPORTUNITIES
• 4.4 CHALLENGES
• 4.5 MACROECONOMIC INDICATORS
• 4.6 TECHNOLOGY TRENDS & ASSESSMENT

5. MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 BARGAINING POWER OF SUPPLIERS
  • 5.1.2 BARGAINING POWER OF BUYERS
  • 5.1.3 THREAT OF NEW ENTRANTS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 INTENSITY OF RIVALRY
• 5.2 VALUE CHAIN ANALYSIS
• 5.3 INVESTMENT FEASIBILITY ANALYSIS
• 5.4 PRICING ANALYSIS

6. GLOBAL MEDICAL MORPHINE MARKET, BY ROUTE OF ADMINISTRATION

• 6.1 INTRODUCTION
• 6.2 ORAL
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
• 6.3 INJECTABLES
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
• 6.4 OTHERS
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030

7. GLOBAL MEDICAL MORPHINE MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 ARTHRITIS
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
• 7.3 CANCER
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
• 7.4 MYOCARDIAL INFARCTION
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
• 7.5 KIDNEY STONES
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
• 7.6 DIARRHEA
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
• 7.7 OTHERS
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030

8. GLOBAL MEDICAL MORPHINE MARKET, BY DISTRIBUTION CHANNEL

• 8.1 INTRODUCTION
• 8.2 HOSPITAL PHARMACY
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
• 8.3 RETAIL PHARMACY
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
• 8.4 ONLINE PHARMACY
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
• 8.5 OTHERS
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030

9. GLOBAL MEDICAL MORPHINE MARKET, BY END-USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS & CLINICS
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
• 9.3 AMBULATORY SURGICAL CENTERS
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
• 9.4 HOMECARE
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030
• 9.5 OTHERS
• MARKET ESTIMATES & FORECAST, 2020-2030
• MARKET ESTIMATES & FORECAST, BY REGION/COUNTRY, 2020-2030

10 GLOBAL MEDICAL MORPHINE MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 AMERICAS
• MARKET ESTIMATES & FORECAST, BY REGION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.2.1 NORTH AMERICA
• MARKET ESTIMATES & FORECAST, BY COUNTRY, 2020-2030
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.2.1.1 U.S.
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.2.1.2 CANADA
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.2.2 SOUTH AMERICA
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
• 10.3 EUROPE
• MARKET ESTIMATES & FORECAST, BY REGION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.3.1 WESTERN EUROPE
• MARKET ESTIMATES & FORECAST, BY COUNTRY, 2020-2030
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.3.1.1 GERMANY
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.3.1.2 FRANCE
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.3.1.3 U.K.
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.3.1.4 ITALY
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.3.1.5 SPAIN
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.3.1.6 REST OF WESTERN EUROPE
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.3.2 EASTERN EUROPE
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
• 10.4 ASIA PACIFIC
• MARKET ESTIMATES & FORECAST, BY COUNTRY, 2020-2030
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.4.1 JAPAN
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.4.2 CHINA
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.4.3 INDIA
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.4.4 AUSTRALIA
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.4.5 REPUBLIC OF KOREA
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.4.6 REST OF ASIA PACIFIC
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
• 10.5 THE MIDDLE EAST & AFRICA
• MARKET ESTIMATES & FORECAST, BY REGION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.5.1 UNITED ARAB EMIRATES
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.5.2 SAUDI ARABIA
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.5.3 OMAN
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.5.4 KUWAIT
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.5.5 QATAR
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030
  • 10.5.6 REST OF THE MIDDLE EAST & AFRICA
• MARKET ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY APPLICATION, 2020-2030
• MARKET ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2020-2030
• MARKET ESTIMATES & FORECAST, BY END-USER, 2020-2030

11 COMPANY LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 MARKET SHARE ANALYSIS
• 11.3 KEY DEVELOPMENT & STRATEGIES
  • 11.3.1 KEY DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 MALLINCKRODT PHARMACEUTICALS
  • 12.1.1 COMPANY OVERVIEW
  • 12.1.2 APPLICATION OVERVIEW
  • 12.1.3 FINANCIALS
  • 12.1.4 SWOT ANALYSIS
• 12.2 ALCALIBER S.A.
  • 12.2.1 COMPANY OVERVIEW
  • 12.2.2 APPLICATION OVERVIEW
  • 12.2.3 FINANCIAL OVERVIEW
  • 12.2.4 KEY DEVELOPMENTS
  • 12.2.5 SWOT ANALYSIS
• 12.3 PURDUE PHARMA L.P.
  • 12.3.1 COMPANY OVERVIEW
  • 12.3.2 APPLICATION OVERVIEW
  • 12.3.3 FINANCIAL OVERVIEW
  • 12.3.4 KEY DEVELOPMENT
  • 12.3.5 SWOT ANALYSIS
• 12.4 PFIZER INC.
  • 12.4.1 COMPANY OVERVIEW
  • 12.4.2 APPLICATION/BUSINESS SEGMENT OVERVIEW
  • 12.4.3 FINANCIAL OVERVIEW
  • 12.4.4 KEY DEVELOPMENT
  • 12.4.5 SWOT ANALYSIS
• 12.5 JOHNSON MATTHEY FINE CHEMICALS
  • 12.5.1 COMPANY OVERVIEW
  • 12.5.2 APPLICATION OVERVIEW
  • 12.5.3 FINANCIAL OVERVIEW
  • 12.5.4 KEY DEVELOPMENTS
• 12.6 SUN PHARMACEUTICAL INDUSTRIES LTD.
  • 12.6.1 COMPANY OVERVIEW
  • 12.6.2 APPLICATION OVERVIEW
  • 12.6.3 FINANCIAL OVERVIEW
  • 12.6.4 KEY DEVELOPMENTS
• 12.7 VERVE HEALTH CARE LTD.
  • 12.7.1 OVERVIEW
  • 12.7.2 APPLICATION OVERVIEW
  • 12.7.3 FINANCIALS
  • 12.7.4 KEY DEVELOPMENTS
  • 12.7.5 SWOT ANALYSIS
• 12.8 TAJ PHARMACEUTICALS LIMITED
  • 12.8.1 OVERVIEW
  • 12.8.2 APPLICATION OVERVIEW
  • 12.8.3 FINANCIALS
  • 12.8.4 KEY DEVELOPMENTS
  • 12.8.5 SWOT ANALYSIS
• 12.9 NORTHEAST PHARM
  • 12.9.1 OVERVIEW
  • 12.9.2 APPLICATION OVERVIEW
  • 12.9.3 FINANCIALS
  • 12.9.4 KEY DEVELOPMENTS
  • 12.9.5 SWOT ANALYSIS
• 12.10 MANUS AKTTEVA BIOPHARMA LLP
  • 12.10.1 OVERVIEW
  • 12.10.2 APPLICATION OVERVIEW
  • 12.10.3 FINANCIALS
  • 12.10.4 KEY DEVELOPMENTS
  • 12.10.5 SWOT ANALYSIS

13 APPENDIX

LIST OF TABLES

• TABLE 1 MEDICAL MORPHINE INDUSTRY SYNOPSIS, 2020-2030
• TABLE 2 GLOBAL MEDICAL MORPHINE MARKET ESTIMATES AND FORECAST, 2020-2030, (USD MILLION)
• TABLE 3 GLOBAL MEDICAL MORPHINE MARKET, BY REGION, 2020-2030, (USD MILLION)
• TABLE 5 GLOBAL MEDICAL MORPHINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, (USD MILLION)
• TABLE 5 GLOBAL MEDICAL MORPHINE MARKET, BY APPLICATION, 2020-2030, (USD MILLION)
• TABLE 6 GLOBAL MEDICAL MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2020-2030, (USD MILLION)
• TABLE 7 GLOBAL MEDICAL MORPHINE MARKET, BY END-USER, 2020-2030, (USD MILLION)
• TABLE 8 NORTH AMERICA MEDICAL MORPHINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, (USD MILLION)
• TABLE 9 NORTH AMERICA MEDICAL MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2020-2030, (USD MILLION)
• TABLE 9 NORTH AMERICA MEDICAL MORPHINE MARKET, BY APPLICATION, 2020-2030, (USD MILLION)
• TABLE 10 NORTH AMERICA MEDICAL MORPHINE MARKET, BY END-USER, 2020-2030, (USD MILLION)
• TABLE 11 U.S. MEDICAL MORPHINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, (USD MILLION)
• TABLE 12 U.S. MEDICAL MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2020-2030, (USD MILLION)
• TABLE 12 U.S. MEDICAL MORPHINE MARKET, BY APPLICATION, 2020-2030, (USD MILLION)
• TABLE 13 U.S. MEDICAL MORPHINE MARKET, BY END-USER, 2020-2030, (USD MILLION)
• TABLE 14 CANADA MEDICAL MORPHINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, (USD MILLION)
• TABLE 14 CANADA MEDICAL MORPHINE MARKET, BY APPLICATION, 2020-2030, (USD MILLION)
• TABLE 15 CANADA MEDICAL MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2020-2030, (USD MILLION)
• TABLE 16 CANADA MEDICAL MORPHINE MARKET, BY END-USER, 2020-2030, (USD MILLION)
• TABLE 17 SOUTH AMERICA MEDICAL MORPHINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, (USD MILLION)
• TABLE 18 SOUTH AMERICA MEDICAL MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2020-2030, (USD MILLION)
• TABLE 19 SOUTH AMERICA MEDICAL MORPHINE MARKET, BY END-USER, 2020-2030, (USD MILLION)
• TABLE 20 EUROPE MEDICAL MORPHINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, (USD MILLION)
• TABLE 21 EUROPE MEDICAL MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2020-2030, (USD MILLION)
• TABLE 22 EUROPE MEDICAL MORPHINE MARKET, BY END-USER, 2020-2030, (USD MILLION)
• TABLE 23 WESTERN EUROPE MEDICAL MORPHINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, (USD MILLION)
• TABLE 24 WESTERN EUROPE MEDICAL MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2020-2030, (USD MILLION)
• TABLE 25 WESTERN EUROPE MEDICAL MORPHINE MARKET, BY END-USER, 2020-2030, (USD MILLION)
• TABLE 26 EASTERN EUROPE MEDICAL MORPHINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, (USD MILLION)
• TABLE 27 EASTERN EUROPE MEDICAL MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2020-2030, (USD MILLION)
• TABLE 28 EASTERN EUROPE MEDICAL MORPHINE MARKET, BY END-USER, 2020-2030, (USD MILLION)
• TABLE 29 ASIA PACIFIC MEDICAL MORPHINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, (USD MILLION)
• TABLE 30 ASIA PACIFIC MEDICAL MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2020-2030, (USD MILLION)
• TABLE 31 ASIA PACIFIC MEDICAL MORPHINE MARKET, BY END-USER, 2020-2030, (USD MILLION)
• TABLE 32 MIDDLE EAST & AFRICA MEDICAL MORPHINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, (USD MILLION)
• TABLE 33 MIDDLE EAST & AFRICA MEDICAL MORPHINE MARKET, BY DIAGNOSES, 2020-2030, (USD MILLION)
• TABLE 34 MIDDLE EAST & AFRICA MEDICAL MORPHINE MARKET, BY END-USER, 2020-2030, (USD MILLION)

LIST OF FIGURES

• FIGURE 1 RESEARCH PROCESS
• FIGURE 2 SEGMENTATION FOR GLOBAL MEDICAL MORPHINE MARKET
• FIGURE 3 SEGMENTATION MARKET DYNAMICS FOR MEDICAL MORPHINE MARKET
• FIGURE 4 GLOBAL MEDICAL MORPHINE MARKET SHARE, BY ROUTE OF ADMINISTRATION 2020
• FIGURE 5 GLOBAL MEDICAL MORPHINE MARKET SHARE, BY APPLICATION 2020
• FIGURE 6 GLOBAL MEDICAL MORPHINE MARKET SHARE, BY END-USER, 2020
• FIGURE 7 GLOBAL MEDICAL MORPHINE MARKET SHARE, BY REGION, 2020
• FIGURE 8 NORTH AMERICA MEDICAL MORPHINE MARKET SHARE, BY COUNTRY, 2020
• FIGURE 9 EUROPE MEDICAL MORPHINE MARKET SHARE, BY COUNTRY, 2020
• FIGURE 10 ASIA PACIFIC MEDICAL MORPHINE MARKET SHARE, BY COUNTRY, 2020
• FIGURE 11 MIDDLE EAST & AFRICA MEDICAL MORPHINE MARKET SHARE, BY COUNTRY, 2020
• FIGURE 12 GLOBAL MEDICAL MORPHINE MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
• FIGURE 13 MALLINCKRODT PHARMACEUTICALS: KEY FINANCIALS
• FIGURE 14 MALLINCKRODT PHARMACEUTICALS: SEGMENTAL REVENUE
• FIGURE 16 MALLINCKRODT PHARMACEUTICALS: GEOGRAPHICAL REVENUE
• FIGURE 17 ALCALIBER S.A. KEY FINANCIALS
• FIGURE 18 ALCALIBER S.A: SEGMENTAL REVENUE
• FIGURE 19 ALCALIBER S.A: GEOGRAPHICAL REVENUE
• FIGURE 20 PFIZER INC.: KEY FINANCIALS
• FIGURE 21 PFIZER INC: SEGMENTAL REVENUE
• FIGURE 22 PFIZER INC: GEOGRAPHICAL REVENUE
• FIGURE 23 SUN PHARMACEUTICAL: KEY FINANCIALS
• FIGURE 24 SUN PHARMACEUTICAL: SEGMENTAL REVENUE
• FIGURE 25 SUN PHARMACEUTICAL: GEOGRAPHICAL REVENUE
• FIGURE 26 VERVE HEALTH CARE LTD.: KEY FINANCIALS
• FIGURE 27 VERVE HEALTH CARE LTD: SEGMENTAL REVENUE
• FIGURE 28 VERVE HEALTH CARE LTD. GEOGRAPHICAL REVENUE